Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease

Journal of Immunology

Volumn 182, Issue 5, 2009, Pages 3024-3031

  Olson, Matthew R ^a   Varga, Steven M ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; FAS LIGAND; GUANINE NUCLEOTIDE BINDING PROTEIN; LIPOCORTIN 5; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VACCINIA VACCINE; ATTACHMENT PROTEIN G; EPITOPE; IMMUNOLOGICAL ADJUVANT; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; LOEFFLER PNEUMONIA; LYMPHOID TISSUE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SYSTEMIC DISEASE; VIRUS ATTACHMENT; ANIMAL; AUTOIMMUNE DISEASE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; COMPARATIVE STUDY; GENETICS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHATIC SYSTEM DISEASE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; EPITOPES, T-LYMPHOCYTE; FAS LIGAND PROTEIN; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; LYMPHATIC DISEASES; MICE; MICE, INBRED BALB C; MICE, MUTANT STRAINS; PULMONARY EOSINOPHILIA; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL ENVELOPE PROTEINS;

EID: 64849084953     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803585     Document Type: Article

References (48)

1. Heilman, C. A. 1990. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J. Infect. Dis. 161: 402-406.
2. Fulginiti, V. A., J. J. Eller, O. F. Sieber, J. W. Joyner, M. Minamitani, and G. Meiklejohn. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89: 435-448.
3. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89: 405-421.
4. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89: 422-434.
5. Chin, J., R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89: 449-463.
6. Walzl, G., S. Matthews, S. Kendall, J. C. Gutierrez-Ramos, A. J. Coyle, P. J. Openshaw, and T. Hussell. 2001. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J. Exp. Med. 193: 785-792.
7. + T cells in mice immunized with respiratory syncytial virus G glycoprotein. J. Leukocyte Biol. 84: 748-759.
8. + T cells. Immunity 15: 637-646.
9. Olson, M. R., and S. M. Varga. 2007. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J. Immunol. 179: 5415-5424.
10. Openshaw, P. J., S. L. Clarke, and F. M. Record. 1992. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4: 493-500.
11. Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson. 1996. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70: 2852-2860.
12. Johnson, T. R., M. N. Teng, P. L. Collins, and B. S. Graham. 2004. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78: 6024-6032.
13. Ferguson, T. A., D. R. Green, and T. S. Griffith. 2002. Cell death and immune privilege. Int. Rev. Immunol. 21: 153-172.
14. Sun, M., and P. J. Fink. 2007. A new class of reverse signaling costimulators belongs to the TNF family. J. Immunol. 179: 4307-4312.
15. Suzuki, I., and P. J. Fink. 1998. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med. 187: 123-128.
16. + T cells. J. Immunol. 165: 5537-5543.
17. + T cells. Proc. Natl. Acad. Sci. USA 97: 1707-1712.
18. + T cell responses through regulated FasL expression. Immunity 23: 649-659.
19. Rutigliano, J. A., and B. S. Graham. 2004. Prolonged production of TNF-α exacerbates illness during respiratory syncytial virus infection. J. Immunol. 173: 3408-3417.
20. Nagata, S., and T. Suda. 1995. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16: 39-43.
21. Peebles, R. S., Jr., J. R. Sheller, R. D. Collins, K. Jarzecka, D. B. Mitchell, and B. S. Graham. 2000. Respiratory syncytial virus (RSV)-induced airway hyperesponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J. Infect. Dis. 182: 671-677.
22. Castilow, E. M., D. K. Meyerholz, and S. M. Varga. 2008. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 180: 2376-2384.
23. Stevens, W. W., T. S. Kim, L. M. Pujanauski, X. Hao, and T. J. Braciale. 2007. Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J. Immunol. Methods 327: 63-74.
24. Hussell, T., A. Pennycook, and P. J. Openshaw. 2001. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31: 2566-2573.
25. + T cells. Clin. Exp. Immunol. 88: 527-536.
26. + T cell responses. J. Immunol. 165: 6487-6495.
27. Kulkarni, A. B., P. L. Collins, I. Bacik, J. W. Yewdell, J. R. Bennink, J. E. Crowe, Jr., and B. R. Murphy. 1995. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J. Virol. 69: 1261-1264.
28. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186: 421-432.
29. + T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol. 78: 8753-8760.
30. + T cells in the lungs following pulmonary virus infection. J. Immunol. 180: 2957-2966.
31. Alwan, W. H., W. J. Kozlowska, and P. J. Openshaw. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179: 81-89.
32. + T cells during infection with respiratory syncytial virus are mediated by IFN-γ. Eur. J. Immunol. 32: 2117-2123.
33. + T cell responses to Fas engagement. Proc. Natl. Acad. Sci. USA 96: 8104-8109.
34. Walsh, C. M., B. G. Wen, A. M. Chinnaiyan, K. O'Rourke, V. M. Dixit, and S. M. Hedrick. 1998. A role for FADD in T cell activation and development. Immunity 8: 439-449.
35. Zhang, J., D. Cado, A. Chen, N. H. Kabra, and A. Winoto. 1998. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392: 296-300.
36. Kennedy, N. J., T. Kataoka, J. Tschopp, and R. C. Budd. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190: 1891-1896.
37. Alam, A., L. Y. Cohen, S. Aouad, and R. P. Sekaly. 1999. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J. Exp. Med. 190: 1879-1890.
38. Sun, M., S. Lee, S. Karray, M. Levi-Strauss, K. T. Ames, and P. J. Fink. 2007. Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-ediated costimulation. J. Immunol. 179: 5639-5643.
39. Sun, M., K. T. Ames, I. Suzuki, and P. J. Fink. 2006. The cytoplasmic domain of Fas ligand costimulates TCR signals. J. Immunol. 177: 1481-1491.
40. Castilow, E. M., K. L. Legge, and S. M. Varga. 2008. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 181: 6692-6696.
41. Janssen, O., R. Sanzenbacher, and D. Kabelitz. 2000. Regulation of activation-nduced cell death of mature T-lymphocyte populations. Cell Tissue Res. 301: 85-99.
42. Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448.
43. Dhein, J., H. Walczak, C. Baumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441.
44. Janssen, O., A. Stocker, R. Sanzenbacher, H. H. Oberg, M. A. Siddiqi, and D. Kabelitz. 2000. Differential regulation of activation-induced cell death in individual human T cell clones. Int. Arch. Allergy Immunol. 121: 183-193.
45. Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, C. F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in Tcell hybridomas. Nature 373: 441-444.
46. + double-negative T cells suppress polyclonal T cell activation by a Fas-independent mechanism that involves inhibition of IL-2 production. J. Immunol. 171: 2421-2426.
47. Ford McIntyre, M. S., K. J. Young, J. Gao, B. Joe, and L. Zhang. 2008. Cutting edge: in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression. J. Immunol. 181: 2271-2275.
48. Waldner, H., R. A. Sobel, E. Howard, and V. K. Kuchroo. 1997. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159: 3100-3103.